The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.
 
Patricia Rioja
No Relationships to Disclose
 
Carolina Passarella
No Relationships to Disclose
 
Martin Angel
No Relationships to Disclose
 
Wbeimar Valderrama
No Relationships to Disclose
 
Freya Bosma
No Relationships to Disclose
 
Georgia Anguera
No Relationships to Disclose
 
Victoria Gomez
No Relationships to Disclose
 
Álvaro Ruiz-Granados
No Relationships to Disclose
 
David Plata
No Relationships to Disclose
 
Martin Zapata Laguado
No Relationships to Disclose
 
Alberto Orta-Ruiz
No Relationships to Disclose
 
Maria Gandur-Quiroga
No Relationships to Disclose
 
Maria Bourlon
Leadership - BMS
Honoraria - BMS; Tecnofarma; Tecnofarma
Consulting or Advisory Role - Asofarma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Gilead Sciences; Gilead Sciences; Janssen Oncology; Merck; MSD; MSD Oncology; Novartis; Novartis; Pfizer
Speakers' Bureau - Asofarma; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ferring; Ipsen; Janssen Oncology; Medicamenta; Merck; MSD Oncology; Pfizer; Tecnofarma
Research Funding - Janssen Oncology (Inst); Pfizer
Expert Testimony - Asofarma
Travel, Accommodations, Expenses - Asofarma; Bristol-Myers Squibb (Mexico); Janssen-Cilag; MSD Oncology; Pfizer
Other Relationship - Sanofi
 
Enrique Grande
Stock and Other Ownership Interests - PharmaMar
Honoraria - Abbott/AbbVie; Abbvie; Advanced Accelerator Applications; Astellas Pharma; AstraZeneca; AVEO; Bristol-Myers Squibb; Dr. Reddy's Laboratories; Eisai; Eusa Pharma; EUSA Pharma; GlaxoSmithKline; IPSEN; Janssen-Cilag; Lilly; Merck KGaA; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; AVEO; Bristol-Myers Squibb; Gilead Sciences; Ipsen; MSD; Pfizer; Roche; Roche
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ipsen (Inst); Lexicon (Inst); Merck KGaA (Inst); Molecular Templates (Inst); Pfizer (Inst); Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Pfizer; Roche/Genentech
 
Ray Manneh
Leadership - Sociedad de Oncología y Hematología del Cesar (I)
Honoraria - Amgen; Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; Tecnofarma
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche; Sanofi; Tecnofarma
Speakers' Bureau - Asociación Colombiana de Hematoligía y Oncología (ACHO); San Jorge Foundation
Research Funding - Amgen; Bristol-Myers Squibb/Celgene; Merck Sharp & Dohme; Novartis; Pfizer
Travel, Accommodations, Expenses - Bayer; Merck Sharp & Dohme; Pfizer; Roche/Genentech
 
Javier Molina-Cerrillo
Consulting or Advisory Role - Adium Pharma; Advanced Accelerator Applications; Astellas Pharma; BMS; Eisai; Ipsen; Janssen; MSD; Pfizer; Sanofi
Speakers' Bureau - BMS; Ipsen; Pfizer
Research Funding - Ipsen (Inst); Janssen (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Pablo Maroto-Rey
Consulting or Advisory Role - Astellas Pharma; Bayer; BMS; Ipsen; Janssen; Merck/Pfizer; MSD
Expert Testimony - Amgen
Travel, Accommodations, Expenses - Bayer; Ipsen; Merck/Pfizer
 
Juan Pablo Sade
No Relationships to Disclose
 
Daniel Castellano
No Relationships to Disclose